Clinical Trials at Miami Valley Hospital South

As of July 2026, 72 paid clinical trials are recruiting at Miami Valley Hospital South in Centerville, Ohio. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

72 clinical trials at Miami Valley Hospital South

·Clear filters·↓ Download CSV

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

415 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

541 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for Lung Non-Small Cell Carcinoma

266 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06498635·Phase 3·Recruiting

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

476 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

451 locations incl. Dayton

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

296 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

408 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for Advanced Lung Non-Small Cell Carcinoma

319 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 70+

Code: NCT06096844·Phase 3·Recruiting

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

321 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

Drug: Cemiplimab

386 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting

Apply to this trial

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for Cardiotoxicity

577 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03418961·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

323 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting

Apply to this trial

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for Extensive Stage Lung Small Cell Carcinoma

148 locations incl. Loma Linda

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06769126·Phase 2·Recruiting

Apply to this trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for Advanced Lung Non-Small Cell Carcinoma

Drug: Osimertinib

345 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03191149·Phase 2·Recruiting

Apply to this trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for Acral Lentiginous Melanoma

Drug: Ipilimumab

331 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04511013·Phase 2·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

373 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

Drug: Cabozantinib

223 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

258 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

266 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18 Minutes+

Code: NCT06031688·Phase 2·Recruiting

Apply to this trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for Recurrent Endometrial Carcinoma

Drug: Selumetinib

293 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05554328·Phase 2·Recruiting

Apply to this trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for Castration Levels of Testosterone

334 locations incl. Gilbert

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT03678025·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

for Metastatic Colorectal Adenocarcinoma

185 locations incl. Kingman

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05673148·Phase 3·Recruiting

Apply to this trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

for Malignant Female Reproductive System Neoplasm

187 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06126276·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

177 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

246 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting

Apply to this trial

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

for Non Small Cell Lung Cancer

Drug: Osimertinib

146 locations incl. Birmingham

Sponsor: PrECOG, LLC.

Sex: All·Age: 18+

Code: NCT06538038·Recruiting

Apply to this trial

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for Endometrial Adenocarcinoma

Drug: Ipilimumab

137 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05112601·Phase 2·Recruiting

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

178 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting

Apply to this trial

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

for Rectal Cancer

105 locations incl. Phoenix

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT06205485·Phase 3·Recruiting

Apply to this trial

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

for Cutaneous Melanoma, Stage II

130 locations incl. Mobile

Sponsor: Melanoma and Skin Cancer Trials Limited

Sex: All·Age: 18+

Code: NCT03860883·Recruiting

Apply to this trial